Performance Characterization of EDA and Its Potential to Improve Decision Making in Product Batch Release - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 241

Fig. 8.71 “Road map” for APSD assessments: answering the question
References
1. US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered
dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and
controls documentation, Rockville, MD, USA. http://www.fda.gov/cder/guidance/2180dft.
pdf . Accessed 15 July 2012
2. Peri P (2011) Assessing quality of inhaled products and links to efficacy and safety. Presentation
at the IPAC-RS Conference “Bringing value to the patient in a changing world”, Rockville,
MD, USA. http://ipacrs.com/2011%20Conference.html . Accessed 13 July 2012
3. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S
(2009) Improved quality control metrics for cascade impaction measurements of orally inhaled
drug products (OIPs). AAPS PharmSciTech 10(4):1276-1285
4. Wheeler DJ (2006) EMP (evaluating the measurement process) III: using imperfect data. SPC,
Knoxville, TN
5. AIAG (Automotive Industry Action Group) (2010) Measurement system analysis, Reference
Manual, 4th edn. AIAG, Southfield, MI, USA, ISBN#: 978-1-60-534211-5
6. Eisenhart C (1963) Realistic evaluation of the precision and accuracy of instrument calibration.
J Res Natl Bur Stds 67C:161-187 [Reprinted, with corrections, in (1969) Precision measure-
ment and calibration: statistical concepts and procedures In: Ku HH (ed) Natl Bur Stds Spec
Publ 300 1:21-48]
7. American Society for Testing and Materials (2012) Standard terminology for relating to
quality and statistics ASTM E456-12, West Conshohocken, PA, USA. http://www.astm.org/
Standards/E456.htm . Accessed 15 July 2012